Medeon Biodesign (ROCO:6499) ROCE %: -41.53% (As of Dec. 2025)

What is Medeon Biodesign ROCE %?

Medeon Biodesign ROCO:6499 68 ROCE % is -41.53% as of Dec. 2025. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.08 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medeon Biodesign's annualized ROCE % for the quarter that ended in Dec. 2025 was -41.53%.

Medeon Biodesign (ROCO:6499) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medeon Biodesign ROCE % Related Terms

Medeon Biodesign ROCE % Historical Data

* Premium members only.

The historical data trend for Medeon Biodesign's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeon Biodesign ROCE % Chart

Medeon Biodesign Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-14.01

-10.79

-38.45

-40.74

-43.65

Medeon Biodesign Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															-50.59	-48.50	-55.45	-57.40	-41.53

68GF Score

Medeon Biodesign Inc ROCO:6499

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Medeon Biodesign ROCE % Calculation

Medeon Biodesign's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-716.011	/	( ( (1877.743 - 215.642)	+	(1779.793 - 160.957) )	/ 2 )
	=	-716.011	/	( (1662.101	+	1618.836)	/ 2 )
	=	-716.011	/	1640.4685
	=	-43.65 %

Medeon Biodesign's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	-615.556	/	( ( (1519.559 - 174.263)	+	(1779.793 - 160.957) )	/ 2 )
	=	-615.556	/	( ( 1345.296	+	1618.836 )	/ 2 )
	=	-615.556	/	1482.066
	=	-41.53 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -41.53% mean?

Medeon Biodesign (ROCO:6499) has a ROCE % of -41.53% as of Dec. 2025.

Is Medeon Biodesign's ROCE % too high?

Medeon Biodesign's current ROCE % is -41.53%. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Medeon Biodesign's ROCE % compare to ISRG and BDX?

Medeon Biodesign's ROCE % of -41.53% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.30, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current ROCE % is -41.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Medeon Biodesign stock overvalued right now?

Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.08, compared to a current price of NT$71.00 — trading 33.7% below its estimated fair value. The current ROCE % is -41.53%. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current ROCE % is -41.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?

Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued. The current stock price of NT$71.00 is trading 33.7% below its estimated GF Value™ of NT$107.08. GuruFocus considers Medeon Biodesign to be Significantly Undervalued.

Key valuation signals for ROCO:6499:

ROCE %: -41.53%
GF Value™: NT$107.08 vs. price of NT$71.00 (33.7% below fair value)
GF Score™: 68/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medeon Biodesign Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ROCO:4126 ROCO:5312 ROCO:4107 ROCO:1565 TPE:4737 TPE:1786 TPE:1783 ROCO:6612 TPE:1752 TPE:4771 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543

Address No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170

Website https://www.medeonbiodesign.com

Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

68GF Score

Get the complete analysis for ROCO:6499

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$71.00

Price

NT$107.08

GF Value

View ROCO:6499 Analysis

See ROCE % data for all stocks →